We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bioverativ Inc. (delisted) | NASDAQ:BIVV | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 104.98 | 101.00 | 104.98 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 28, 2017
Bioverativ Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
(State or other jurisdiction of incorporation) |
||
|
||
001-37859 |
|
81-3461310 |
(Commission File Number) |
|
(IRS Employer Identification No.) |
225 Second Avenue, Waltham, Massachusetts 02451 |
Not Applicable |
(Address of principal executive offices; Zip Code) |
(Former name or former address, if changed since last report.) |
Registrant’s telephone number, including area code: (781) 663-4400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Explanatory Note
On June 29, 2017, Bioverativ Inc. (“Bioverativ”) filed a Current Report on Form 8-K (the “Original Report”) with the Securities and Exchange Commission (“SEC”) to report that effective as of June 28, 2017, Bioverativ completed the acquisition of True North Therapeutics, Inc. (“True North”) through the merger of TITN Merger Sub, Inc., a wholly-owned subsidiary of Bioverativ, with and into True North (the “Merger”).
This amendment to the Original Report is being filed to provide the financial statements and pro forma financial information required by Items 9.01(a) and 9.01(b), respectively, of Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(a) Financial Statements of Business Acquired
The audited financial statements of True North as of and for the years ended December 31, 2016 and 2015, the accompanying notes thereto, and the related Report of Independent Registered Public Accounting Firm, are filed herewith as Exhibit 99.1 to this Current Report on Form 8-K/A. The unaudited financial statements of True North as of and for the three months ended March 31, 2017, and the accompanying notes thereto, are filed as Exhibit 99.2 to this Current Report on Form 8-K/A.
(b) Pro Forma Financial Information
The following unaudited pro forma condensed combined financial information giving effect to the Merger is filed herewith as Exhibit 99.3 to this Current Report on Form 8-K/A:
|
· |
|
Unaudited pro forma condensed combined statement of income for the three months ended March 31, 2017; |
|
· |
|
Unaudited pro forma condensed combined statement of income for the year ended December 31, 2016; and |
|
· |
|
Notes to unaudited pro forma condensed combined financial information. |
(d) Exhibits.
The following exhibits are filed as part of the current report:
|
|
|
Exhibit No. |
|
Description |
|
|
|
23.1 |
|
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm |
|
|
|
99.1 |
|
True North’s audited financial statements as of and for the years ended December 31, 2016 and 2015 |
|
|
|
99.2 |
|
True North’s unaudited financial statements as of and for the three months ended March 31, 2017 |
|
|
|
99.3 |
|
Unaudited pro forma condensed combined financial information of Bioverativ |
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
BIOVERATIV INC. |
|
|
|
|
By: |
/s/ John T. Greene |
|
|
John T. Greene |
|
|
Executive Vice President,
|
|
|
|
Date: September 14, 2017 |
|
|
1 Year Bioverativ Inc. Chart |
1 Month Bioverativ Inc. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions